VYNE Therapeutics Inc Forecast, price target & analysts
VYNE Therapeutics Inc Target price 2026 - Analyst rating & recommendation
VYNE Therapeutics Inc Classifications & Recommendation
VYNE Therapeutics Inc Price Target
| Target Price | $2.04 |
| Price | $22.27 |
| Deviation |
90.84%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target VYNE Therapeutics Inc 2027 .
The average VYNE Therapeutics Inc target price is $2.04.
This is
90.84%
register free of charge
$2.10
90.57%
register free of charge
$2.02
90.93%
register free of charge
|
|
| A rating was issued by 8 analysts: 6 Analysts recommend VYNE Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the VYNE Therapeutics Inc stock has an average upside potential 2027 of
90.84%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.57 | 0.71 |
| 14.00% | 25.26% | |
| EBITDA Margin | -5,215.79% | -7,242.86% |
| 40.23% | 38.86% | |
| Net Margin | -4,645.61% | -4,359.32% |
| 41.68% | 6.16% |
3 Analysts have issued a sales forecast VYNE Therapeutics Inc 2026 . The average VYNE Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an VYNE Therapeutics Inc EBITDA forecast 2026. The average VYNE Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
| 2025 | -5,215.79% | 40.23% |
|---|---|---|
| 2026 |
-7,242.86%
38.86%
unlock
|
|
4 VYNE Therapeutics Inc Analysts have issued a net profit forecast 2026. The average VYNE Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.63 | -0.93 |
| 32.26% | 47.62% | |
| P/E | negative |
4 Analysts have issued a VYNE Therapeutics Inc forecast for earnings per share. The average VYNE Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
VYNE Therapeutics Inc...
Current VYNE Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 30 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 25 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 23 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 30 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 25 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 23 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
